



Clinical Features and Long-Term Outcomes of Systemic Lupus Erythematosus

Guest Editors:

Prof. Dr. Christopher Sjöwall

Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, SE-581 85 Linköping, Sweden

Dr. Ioannis Parodis

Department of Medicine Solna, Division of Rheumatology, Karolinska Institutet and Karolinska University Hospital, SE-171 76 Stockholm, Sweden

Deadline for manuscript submissions:

closed (31 March 2022)

Message from the Guest Editors

The clinical spectrum of systemic lupus erythematosus (SLE) is highly heterogeneous. The clinical manifestations range from skin and joint involvement to life-threatening conditions such as renal or neuropsychiatric disease, severe cytopenias and thromboembolic events. Despite advances in pharmacotherapy, SLE is still characterized by premature mortality and substantially reduced health-related quality of life. The unmet needs are many. Development of effective drugs that can induce remission or low disease activity is imperative, but has been challenging due to the heterogeneity of the disease, among other reasons. Effective management of flares, identification of biomarkers of disease activity and long-term outcomes, as well as implementation of the patient perspective as an integral part of the clinical assessment constitute only few of the goals towards optimized management.

This Special Issue aims to provide current and new knowledge on clinical features and outcomes of SLE, including disease phenotypes, therapeutic strategies, and biomarkers of activity, treatment response and prognosis. Research incorporating the COVID-19 pandemic and its consequences is also welcome.





an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department,
University Hospital Strasbourg,
67081 Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and
Critical Care Medicine, The
University of Tokyo, Tokyo, Japan

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's (JCM)* staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Contact Us

Journal of Clinical Medicine Editorial
Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jcm
jcm@mdpi.com
[X@JCM_MDPI](https://twitter.com/JCM_MDPI)